EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study

Vincent R Lanting, Floris T M Bosch, Emily S L Martens, Pieter W Kamphuisen, Stefano Barco, Ramón Lecumberri, Hans-Martin Otten, Francesca Schieppati, Corrado Lodigiani, María Barca-Hernando, Elena Campello, Frederikus A Klok und 5 weitere

Journal of Thrombosis and Haemostasis · 2025-12 · 23 (12) · 3932-3939

DOI: 10.1016/j.jtha.2025.08.022 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-12. Verfasst von Vincent R Lanting und 16 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam University Medical Centers, University of Amsterdam, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, the Net…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Heparin, Low-Molecular-Weight, Anticoagulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Society on Thrombosis and Haemostasis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). OBJECTIVES: We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs. METHODS: This was an international, prospective, observational cohort study. Patients were treated according to local practice, although the study protocol encouraged the use of a dose-escalation strategy in accordance with current clinical guidelines. Primary outcomes were second recurrent VTE and clinically relevant bleeding. RESULTS: Between June 2020 and November 2024, 94 patients were enrolled, of whom 81 were included in the final analysis. At the time of recurrent VTE, 55% of patients were treated with a DOAC, 41% with therapeutic-dose LMWH, and 4% with maintenance-dose LMWH. Of DOAC-treated patients, 51% switched to supratherapeutic-dose LMWH, 42% to therapeutic-dose LMWH, and 7% received other treatments. Of LMWH-treated patients, 70% received dose escalation, 18% maintained the same dose, and 12% received other treatments. At the 3-month follow-up, 10% had developed a second recurrence, 12% clinically relevant bleeding, and 20% died. VTE incidence was similar between patients receiving dose escalation and those maintained on therapeutic doses, while clinically relevant bleeding was more frequent in the latter (6% vs 25%). CONCLUSION: The risk of second recurrent VTE was substantial despite two-thirds of patients receiving dose escalation. Bleeding was common regardless of treatment intensity, underscoring the challenges in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsHeparin, Low-Molecular-WeightAnticoagulantsFactor Xa InhibitorsHumansProspective StudiesFemaleMaleRecurrenceMiddle AgedAgedHemorrhageTreatment OutcomeRisk FactorsAdministration, OralTime FactorsAged, 80 and over

Stichwörter der Autor:innen

anticoagulantsdirect oral anticoagulantslow-molecular-weight heparinneoplasmsvenous thromboembolism

Substanzen

Heparin, Low-Molecular-WeightAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Amsterdam University Medical Centers, University of Amsterdam, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; Tergooi MC, Department of Internal Medicine, Hilversum, the…
  • Department of Medicine, Thrombosis & Hemostasis, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Angiology, University Hospital Zurich, Zurich, Switzerland.
  • Hematology Service, Cancer Center Universidad de Navarra, Pamplona, Spain.
  • Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, Netherlands.
  • Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.

Förderung

  • International Society on Thrombosis and Haemostasis

Zitieren

APA

Lanting, V. R., Bosch, F. T. M., Martens, E. S. L., Kamphuisen, P. W., Barco, S., Lecumberri, R., Otten, H. M., Schieppati, F., Lodigiani, C., Barca-Hernando, M., Campello, E., Klok, F. A., Jara-Palomares, L., Porreca, E., Büller, H. R., van Es, N., & Di Nisio, M. (2025). Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study. Journal of Thrombosis and Haemostasis, 23(12), 3932-3939. https://doi.org/10.1016/j.jtha.2025.08.022

Vancouver

Lanting VR, Bosch FTM, Martens ESL, Kamphuisen PW, Barco S, Lecumberri R, et al. Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study. Journal of Thrombosis and Haemostasis. 2025;23(12):3932-3939. doi:10.1016/j.jtha.2025.08.022

BibTeX
@article{Lanting2025,
  author = {Lanting, Vincent R and Bosch, Floris T M and Martens, Emily S L and Kamphuisen, Pieter W and Barco, Stefano and Lecumberri, Ramón and Otten, Hans-Martin and Schieppati, Francesca and Lodigiani, Corrado and Barca-Hernando, María and Campello, Elena and Klok, Frederikus A and Jara-Palomares, Luis and Porreca, Ettore and Büller, Harry R and van Es, Nick and Di Nisio, Marcello},
  title = {Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {12},
  pages = {3932--3939},
  doi = {10.1016/j.jtha.2025.08.022}
}
Kostenlos starten →